Oncology PulsePoints: Multiple Myeloma ASCO-Ontario Living Guideline Updates
ASCO guidelines reshape multiple myeloma care with quadruplet induction, earlier CAR T-cell therapy and bispecifics, and selective smoldering treatment.
Multiple myeloma (MM) treatment has undergone a dramatic transformation, with data from over 150 randomized controlled trials informing the latest joint guidelines from the American Society of Clinical Oncology and Cancer Care Ontario. From quadruplet induction regimens to chimeric antigen receptor (CAR) T-cell therapy, bispecifics, and early treatment of high-risk smoldering myeloma, the landscape has never been more complex. Pharmacy Times spoke with Sanja Zepcan, PharmD, BCPS, BCOP, bone marrow transplant and cellular therapy clinical pharmacy specialist at Loyola Medicine, about the key updates in the living guideline, what they mean for real-world practice, and the increasingly central role pharmacists play in navigating the clinical, operational, and financial complexity of modern myeloma care.